ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
Seroprevalence of tick-borne encephalitis virus and vaccination coverage of tick-borne encephalitis, Sweden, 2018 to 2019.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Tick-borne encephalitis in the Åland Islands, Finland: incidence and disease course since the implementation of a general TBE vaccination programme.Emerging microbes & infections · 2026Article
- Tick-Borne Encephalitis (TBE) Vaccine in the National Immunisation Programme-For Whom, When and Where?Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Article
- Reassessing Regional Tick-Borne Encephalitis Endemicity in Poland Through Seroprevalence Analysis in Blood Donors, 2021-2022.Pathogens (Basel, Switzerland) · 2026Article
- Fatal European subtype tick-borne encephalitis in a fully vaccinated immunocompetent child: a case report with viral sequencing.BMC infectious diseases · 2026Article
- Projecting tick-borne encephalitis risk in Sweden under climate change scenarios: a high-resolution spatio-temporal modeling approach.Environmental health : a global access science source · 2026Article
- Seroprevalence of seven climate-sensitive zoonoses in Greenland and northern Sweden (1998-2017): High antibody prevalence againstOne health (Amsterdam, Netherlands) · 2025Article
- Seroprevalence of Tick-Borne Encephalitis Virus in Latvia Using Standard and Subtype-Specific NS1-Based ELISA Assays.Pathogens (Basel, Switzerland) · 2025Article
- Fast-Track to Protection? A Review of Encepur's Express Dosing Schedule for Tick-Borne Encephalitis.Viruses · 2025Review
- Tick-borne encephalitis virus associated with foetal death in a bitch, a case report.Virology journal · 2025Article
- Article
- Surveillance of Tick-Borne Encephalitis Virus-Comparison of Vaccination- and Infection-Induced Seroprevalences in Lower Bavaria, Germany.Journal of medical virology · 2025Article
- Clinical Spectrum and Dynamics of Sequelae Following Tick-Borne Encephalitis Virus Infection: A Systematic Literature Review.Open forum infectious diseases · 2025Article
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021.Scientific reports · 2025Article
- Clinical Characteristics of Tick-Borne Encephalitis in Adult Patients: A 10-year Retrospective Study in Stockholm, Sweden.The Journal of infectious diseases · 2025Article
- Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022.Scientific reports · 2025Article
- What makes patients tick? Vaccine preferences against tick-borne encephalitis in four European countries.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundIn Sweden, information on seroprevalence of tick-borne encephalitis virus (TBEV) in the population, including vaccination coverage and infection, is scattered. This is largely due to the absence of a national tick-borne encephalitis (TBE) vaccination registry, scarcity of previous serological studies and use of serological methods not distinguishing between antibodies induced by vaccination and infection. Furthermore, the number of notified TBE cases in Sweden has continued to increase in recent years despite increased vaccination.AimThe aim was to estimate the TBEV seroprevalence in Sweden.MethodsIn 2018 and 2019, 2,700 serum samples from blood donors in nine Swedish regions were analysed using a serological method that can distinguish antibodies induced by vaccination from antibodies elicited by infection. The regions were chosen to reflect differences in notified TBE incidence.ResultsThe overall seroprevalence varied from 9.7% (95% confidence interval (CI): 6.6-13.6%) to 64.0% (95% CI: 58.3-69.4%) between regions. The proportion of vaccinated individuals ranged from 8.7% (95% CI: 5.8-12.6) to 57.0% (95% CI: 51.2-62.6) and of infected from 1.0% (95% CI: 0.2-3.0) to 7.0% (95% CI: 4.5-10.7). Thus, more than 160,000 and 1,600,000 individuals could have been infected by TBEV and vaccinated against TBE, respectively. The mean manifestation index was 3.1%.ConclusionA difference was observed between low- and high-incidence TBE regions, on the overall TBEV seroprevalence and when separated into vaccinated and infected individuals. The estimated incidence and manifestation index argue that a large proportion of TBEV infections are not diagnosed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.